Scientists from the Aaron Diamond AIDS Research Center have described bispecific antibodies that were able to neutralize more than 100 HIV strains at very low concentrations, suggesting that such antibodies might be useful for either treatment of HIV-infected individuals or pre-exposure prophylaxis.